Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP HARADA, Paulo H. FMUSP-HC
MILL, Jose G.
LOTUFO, Paulo A. FMUSP-HC 2019
dc.identifier.citation ATHEROSCLEROSIS, v.284, p.59-65, 2019
dc.identifier.issn 0021-9150
dc.description.abstract Background and aims: It is uncertain whether non-alcoholic fatty liver disease (NAFLD) is associated with aortic stiffness in a racial/ethnically diverse and admixed society. We addressed whether NAFLD presence and severity were associated with carotid-femoral pulse wave velocity (cf-PWV) in individuals free of cardiovascular disease. Methods: In 7196 individuals free of cardiovascular disease at the baseline Brazilian longitudinal study of adult health, we classified NAFLD presence and severity (mild, moderate and severe) by ultrasound hepatic attenuation. We measured cf-PWV using a non-invasive validated device (Complior SP, Artech Medicale France). We compared cf-PWV of NAFLD individuals to those without by analysis of covariance adjusted for demographics, life style, waist circumference, and arterial pressure. We also analyzed the cf-PWV trend from no-NAFLD to severe NAFLD. Results: In unadjusted analysis, from no-NAFLD to severe NAFLD, there were slightly older individuals, lower frequency of smokers, more prevalent diabetes and hypertension. In adjusted analysis, there was slightly higher cf-PWV (m/s) (95% CI) in NAFLD vs. no-NAFLD, respectively 9.32 (9.22, 9.41) and 9.24 (9.15, 9.33) (p= 0.037). Across NAFLD severity spectrum, adjusted cf-PWV increased from 9.24 (9.15, 9.33) in no-NAFLD to 9.69 (9.46, 9.93) in severe NAFLD (p for trend association= 0.001). In sensitivity analysis, diabetes adjustment nullified the association of binary NAFLD with cf-PWV, but not that of increasingly severe NAFLD. Conclusions: In racial/ethnically diverse individuals free of cardiovascular disease, NAFLD is associated with aortic stiffness beyond abdominal obesity. The specific NAFLD impact on CVD worldwide is potentially relevant.
dc.description.sponsorship · Brazil Health Ministry
· Brazil Science and Technology Ministry (Financiadora de Estudos e Projetos)
· Brazil Science and Technology Ministry (CNPq National Research Council) [01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP, 01 06 0071.00 RJ]
dc.language.iso eng
dc.relation.ispartof Atherosclerosis
dc.rights restrictedAccess
dc.subject Non-alcoholic fatty liver disease; Hepatic steatosis; Aortic stiffness; Carotid femoral pulse wave velocity; Subclinical cardiovascular disease; Obesity; Race/ethnical diversity
dc.subject.other increased arterial stiffness; pulse-wave velocity; cardiovascular events; follow-up; metabolic syndrome; risk; interleukin-6; mortality; atherosclerosis; organization
dc.title Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil
dc.type article
dc.rights.holder Copyright ELSEVIER IRELAND LTD LIM/09 LIM/20 LIM/51
dc.identifier.doi 10.1016/j.atherosclerosis.2019.02.005
dc.identifier.pmid 30875494
dc.type.category original article
dc.type.version publishedVersion HARADA, Paulo H.:HU: BENSENOR, Isabela J. M.:FM:MCM DRAGER, Luciano F.:FM:MCM GOULART, Alessandra C.:HU:SCPACEX-62 LOTUFO, Paulo A.:FM:MCM · MILL, Jose G.:Univ Fed Espirito Santo, Dept Physiol Sci, 1468 Marechal Campos Ave, BR-29042755 Vitoria, ES, Brazil WOS:000466155400009 2-s2.0-85062821557 CLARE IRELAND
hcfmusp.relation.reference · Arner P, 2015, INT J OBESITY, V39, P222, DOI 10.1038/ijo.2014.118
· Baldo MP, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005477
· Baldo MP, 2018, INT J CARDIOL, V251, P90, DOI 10.1016/j.ijcard.2017.10.075
· Bedogni G, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-33
· BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288
· Ben-Shlomo Y, 2014, J AM COLL CARDIOL, V63, P636, DOI 10.1016/j.jacc.2013.09.063
· Bensenor IM, 2013, REV SAUDE PUBL, V47, P37, DOI 10.1590/S0034-8910.2013047003780
· Betticher DC, 2006, BRIT J CANCER, V94, P1099, DOI 10.1038/sj.bjc.6603075
· Cecelja M, 2009, HYPERTENSION, V54, P1328, DOI 10.1161/HYPERTENSIONAHA.109.137653
· Fedeli LG, 2013, REV SAUDE PUBL, V47, P63, DOI 10.1590/S0034-8910.2013047003807
· Gerli R, 2000, MECH AGEING DEV, V121, P37
· Goulart AC, 2015, SAO PAULO MED J, V133, P115, DOI 10.1590/1516-3180.2014.9150812
· Hamaguchi M, 2007, WORLD J GASTROENTERO, V13, P1579, DOI 10.3748/wjg.v13.i10.1579
· Harada PHN, 2017, J CLIN LIPIDOL, V11, P1257, DOI 10.1016/j.jacl.2017.06.008
· Haukeland JW, 2006, J HEPATOL, V44, P1167, DOI 10.1016/j.jhep.2006.02.011
· Huang Y, 2012, ARTERIOSCL THROM VAS, V32, P2321, DOI 10.1161/ATVBAHA.112.252957
· Jarrar MH, 2008, ALIMENT PHARM THER, V27, P412, DOI 10.1111/j.1365-2036.2007.03586.x
· Joy D, 2003, EUR J GASTROEN HEPAT, V15, P539, DOI 10.1097/01.meg.0000059112.41030.2e
· Khot UN, 2003, JAMA-J AM MED ASSOC, V290, P898, DOI 10.1001/jama.290.7.898
· Kim BJ, 2012, CARDIOLOGY, V123, P54, DOI 10.1159/000341248
· Kim NH, 2014, HEART, V100, P938, DOI 10.1136/heartjnl-2013-305099
· Lazo M, 2008, SEMIN LIVER DIS, V28, P339, DOI 10.1055/s-0028-1091978
· Lee YJ, 2012, DIGEST DIS SCI, V57, P196, DOI 10.1007/s10620-011-1819-3
· Long MT, 2015, ARTERIOSCL THROM VAS, V35, P1284, DOI 10.1161/ATVBAHA.114.305200
· Lotufo PA, 2013, REV SAUDE PUBL, V47, P3, DOI 10.1590/S0034-8910.2013047S20002
· Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
· Mantovani A, 2018, DIABETES CARE, V41, P372, DOI 10.2337/dc17-1902
· Mill JG, 2013, REV SAUDE PUBL, V47, P54, DOI 10.1590/S0034-8910.2013047003851
· Mitchell GF, 2010, CIRCULATION, V121, P505, DOI 10.1161/CIRCULATIONAHA.109.886655
· Ong JP, 2008, J HEPATOL, V49, P608, DOI 10.1016/j.jhep.2008.06.018
· Oni ET, 2013, ATHEROSCLEROSIS, V230, P258, DOI 10.1016/j.atherosclerosis.2013.07.052
· Ozturk K, 2015, ATHEROSCLEROSIS, V240, P380, DOI 10.1016/j.atherosclerosis.2015.04.009
· Rafiq N, 2009, CLIN GASTROENTEROL H, V7, P234, DOI 10.1016/j.cgh.2008.11.005
· Ridker PM, 2016, CIRC RES, V118, P145, DOI 10.1161/CIRCRESAHA.115.306656
· Saadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354
· Salvi P, 2010, J HYPERTENS, V28, P1699, DOI 10.1097/HJH.0b013e32833a7de6
· Sarwar N, 2012, LANCET, V379, P1205, DOI 10.1016/S0140-6736(11)61931-4
· Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
· Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023
· Soderberg C, 2010, HEPATOLOGY, V51, P595, DOI 10.1002/hep.23314
· Swerdlow DI, 2012, LANCET, V379, P1214, DOI 10.1016/S0140-6736(12)60110-X
· Targher G, 2006, DIABETES CARE, V29, P1325, DOI 10.2337/dc06-0135
· Targher G, 2005, DIABETES, V54, P3541, DOI 10.2337/diabetes.54.12.3541
· Targher G, 2016, J HEPATOL, V65, P589, DOI 10.1016/j.jhep.2016.05.013
· Vlachopoulos C, 2010, AM J HYPERTENS, V23, P1183, DOI 10.1038/ajh.2010.144
· Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061
· Wang M, 2007, HYPERTENSION, V50, P219, DOI 10.1161/HYPERTENSIONAHA.107.089409
· Wendt Thoralf, 2002, Curr Atheroscler Rep, V4, P228, DOI 10.1007/s11883-002-0024-4
· Yki-Jarvinen H, 2014, LANCET DIABETES ENDO, V2, P901, DOI 10.1016/S2213-8587(14)70032-4
· Zeb I, 2016, J AM COLL CARDIOL, V67, P1965, DOI 10.1016/j.jacc.2016.01.070
dc.description.index MEDLINE
dc.identifier.eissn 1879-1484
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 1 Brasil

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account